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Abstract
In a previous study, we have shown that human neural stem cells (hNSCs) transplanted in brain of mouse intracerebral
hemorrhage (ICH) stroke model selectively migrate to the ICH lesion and induce behavioral recovery. However, low survival
rate of grafted hNSCs in the brain precludes long-term therapeutic effect. We hypothesized that hNSCs overexpressing Akt1
transplanted into the lesion site could provide long-term improved survival of hNSCs, and behavioral recovery in mouse ICH
model. F3 hNSC was genetically modified with a mouse Akt1 gene using a retroviral vector. F3 hNSCs expressing Akt1 were
found to be highly resistant to H2O2-induced cytotoxicity in vitro. Following transplantation in ICH mouse brain, F3.Akt1
hNSCs induced behavioral improvement and significantly increased cell survival (50–100% increase) at 2 and 8 weeks post-
transplantation as compared to parental F3 hNSCs. Brain transplantation of hNSCs overexpressing Akt1 in ICH animals
provided functional recovery, and survival and differentiation of grafted hNSCs. These results indicate that the F3.Akt1
human NSCs should be a great value as a cellular source for the cellular therapy in animal models of human neurological
disorders including ICH.
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Introduction
Two major types of stroke are cerebral infarction (ischemia) and
intracerebral hemorrhage (ICH). ICH causes severe neurological
deficits and extensive death rate in patients. Since medical therapy
against ICH such as mechanical removal of hematoma, prevention
of edema formation by drugs and reduction of intracranial
pressure shows only limited effectiveness, alternative approach is
required such as stem cell-based cell therapy [1,2].
Recent progress in stem cell biology has opened up a new way
to therapeutic strategies to replace lost neural cells by transplan-
tation of neural stem cells (NSCs) in CNS injury and disease [3–8].
Previous studies have indicated that NSCs or neural progenitor
cells engrafted in animal models of stroke survive and ameliorate
neurological deficits in the animals [9–17]. Among these studies,
human neural progenitor cells isolated from fetal brain have been
transplanted into the brain of stroke animal models and found to
restore brain function [13,14]. This approach, however, is not
widely acceptable for stroke patients because of moral, religious
and logistic problems associated with the use of human fetal
tissues. In addition, primary human NSCs derived from fetal
tissues can be provided for only a limited time before they undergo
senescence, and it is difficult to secure sufficient numbers and
homogeneous populations of human NSCs from fetal brain. These
problems can be circumvented by the use of stable, permanent cell
lines of human NSCs. We have previously reported that human
NSC line ameliorate neurological deficits in animal models of
Parkinson disease [18], Huntington disease [19,20], amyotrophic
lateral sclerosis [21] and lysosomal storage disease [22] following
their transplantation into the brain or spinal cord. In stroke animal
models, intravenously transplanted human NSCs migrated
selectively to the damaged brain sites caused by ischemia and
ICH, differentiated into neurons and astrocytes, and promoted
functional recovery in these animals [9–12,15–17]. However, low
survival rate of grafted F3 NSCs in ischemia and ICH rats in the
previous studies is a grave concern; less than 50% of grafted NSCs
survived in ICH mice at 2-weeks post transplantation and 30% at
8-weeks [15,16].
One possible way to promote extended survival of transplanted
NSCs in animal brain is to modulate properties of the NSCs, and
this might be accomplished by over-expressing Akt1 protein which
is known as a general mediator of cell survival signals in the NSCs.
Akt, a serine/threonine kinase, plays a critical role in the
modulation of cell proliferation, growth, and survival. The
PI3K-Akt signal pathway is well-known for the cell survival and
it exhibits anti-apoptotic effects against a variety of apoptotic
paradigms including withdrawal of extracellular signaling factors,
oxidative and osmotic stress, irradiation and ischemic shock [23–
26]. Previous studies have demonstrated that overexpression of
Akt prevents cerebellar granule cells from apoptotic cell death
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during free radical exposure to free radical or hypoxia in
hippocampal neurons [27–29].
Considering evidence of functional recovery in stroke animals
following brain transplantation of human NSCs and Akt1 protein
as a general mediator of survival signals, the present study is
designed to investigate whether human NSCs overexpressing Akt1
can lead to the prolonged cell survival of grafted human NSCs and
functional recovery in the mouse ICH stroke model.
Materials and Methods
Cell culture
Primary dissociated cell cultures of fetal human brain tissues of 14
weeks gestation were prepared as described previously [30,31]. The
cells weregrown inT25 flasksinDulbecco’smodifiedEagle medium
with high glucose (DMEM; HyClone, Logan, UT), 5% fetal bovine
serum (FBS) and 20 mg/ml gentamicin (Sigma, St Louis, MO)
(Sigma). The medium was changed twice a week. The permission to
use the fetal tissues was granted by the Clinical Research Screening
Committee involving Human Subjects of the University of British
Columbia, and the fetal tissues were obtained from the Anatomical
Pathology Department of Vancouver General Hospital.
Stable, immortal human neural stem cell line, HB1.F3 (F3), was
generated from the primary fetal human brain cell culture as
described previously [15,32–34]. PA317 amphotropic packaging
cell line was infected with the recombinant replication-incompe-
tent retroviral vector pLNX.v-myc, and the supernatants from the
packaging cells were used to infect NSCs in human telencephalon
cultures. Stably transfected colonies were selected by neomycine
resistance. Several stable clones of human NSCs (hNSCs) were
isolated, and one of them, HB1.F3 (F3 hereafter), was expanded
for the present study. F3 hNSCs express ABCG2, nestin and
Musashi1, which are cell type specific markers for NSCs [15,34].
To generate Akt1 overexpressing hNSC line (F3.Akt1), Akt1
cDNA (Upstate, Charlottesville, VA) was ligated into multiple
cloning sites of the retroviral vector pLHCX (Clontech, Mountain
View, CA). Before the ligation, mouse Akt1 cDNA was PCR-
amplified by using forward primer 59-CTAGTTAAGCT-
TATGGGGAGCAGC-39; reverse primer 59- GATATGATC-
GATTGATC AGAGGGTTTA -39. PA317 amphotropic pack-
aging cell line was infected with the recombinant retroviral vector,
and the supernatants from the packaging cells were added to the
F3 hNSCs. Stably transfected colonies were selected by hygro-
mycin resistance.
RT-PCR analysis
Reverse transcription was performed with M-MLV reverse
transcriptase (Promega, Madison, WI) for 1 hr at 42uC, inactivat-
ed for 15 min at 95uC and cooled at 4uC. PCR reaction solution
consisted of DNA polymerase buffer, containing cDNA 1 mL,
5 mM MgCl2, 1 mM dNTPs, 10 pM primers and 2.5 units Taq
polymerase (Promega). The cDNA was amplified using 30 PCR
cycles and RT-PCR products were separated electrophoretically
on 1.2% agarose gel containing ethidium bromide and visualized
under UV light. The primers used for the RT-PCR for nestin,
neurofilament (NF)-L, NF-M, NF-H, glial fibrillary acidic protein
(GFAP), GAPDH and Akt1 are listed in Table 1.
Hydrogen peroxide treatment
F3 and F3.Akt1 cells were plated 1610
4 cells per well in 96 well-
plates (Falcon, Becton Dickinson, Franklin lakes, NJ) with DMEM
containing 5% FBS and incubated for overnight. Hydrogen
peroxide (Sigma) was added to each well containing F3 and
F3.Akt1 cells to give a final H2O2 concentration in the range from
0 to 0.5 mM. Control wells contained normal medium. Cells were
left for 6 hr and 24 hr for viability assay and for 6 hr for western
blot analysis.
Cell viability assay
Cell viability was determined by the conversion of MTT [3-(4,5-
dimethylthiaxol-2-yl)-2,5 diphenyl tetrazolium bromide] to form-
azan utilizing NADH and NADPH pyridine nucleotide cofactors.
After stimulation with H2O2 at different dose for 6 or 24 hr, MTT
[2 mg/ml in phosphate buffered saline (PBS)] was added to each
well and incubated for 2 hr. The media containing MTT was
removed, 100 mL of dimethyl sulfoxide (DMSO, Sigma) added to
each well and absorbance read at 570 nm.
Western blot analysis
Western blot analysis was performed with 50 mg total protein
extract separated on 10% SDS-PAGE gels that were subsequently
transferred to polyvinylidene difluoride (PVDF) membrane (Milli-
pore, Billerica, MA). Blocking of membranes with 5% skim milk in
TBST and washed in TBST, membranes were incubated with
anti-phospho-Akt1-Thr 308 (1:500, Upstate), anti-caspase-3
(1:1000, Chemicon) and anti-beta-actin antibody (1:10,000, Santa
Cruz) at 4uC overnight, membrane washed in Tris-buffered saline
containing 0.05% tween 20 for 1 hr at RT, then incubated in
secondary antibody [horseradish peroxidase-conjugated anti-
rabbit or anti-mouse IgG] (Sigma) for 2 hr at RT. Immunoreac-
tive bands were detected by chemiluminescence using ECL
system. Western blots analyses were performed on samples from
twice separate experiments.
Mouse intracerebral hemorrhage stroke model
All experimental procedures were approved by the Animal Care
Committee of the University of British Columbia. ICH was
induced by stereotaxic, intrastriatal administration of bacterial
collagenase by previously described methods [12,16,17]. In brief,
after an intraperitoneal injection of 1% ketamine (30 mg/kg) and
xylazine hydrochloride (4 mg/kg), the mice were placed in a
stereotaxic frame (Kopf Instruments, Tujunga, CA). A burr hole
Table 1. PCR primer sequences for cell type-specific markers
(all human).
Gene Sequence
Akt1 Sense: 59-ACCTCTGAGACTGACACCATG-39
Antisense: 59-CACTGGCTGAGTAGGAGAAC-39
Nestin Sense: 59-CTCTGACCTGTCAGAAGAAT-39
Antisense: 59-GACGCTGACACTTACAGAAT-39
NF-L Sense: 59-TCCTACTACACCAGCCATGT-39
Antisense: 59-TCCCCAGCACCTTCAACTTT-39
NF-M Sense: 59-TGGGAAATGGCTCGTCATTT-39
Antisense: 59-CTTCATGGAAGCGGCCAATT-39
NF-H Sense: 59-CTGGACGCTGAGCTGAGGAA-39
Antisense: 59-CAGTCACTTCTTCAGTCACT-39
GFAP Sense: 59-GCAGAGATGATGGAGCTCAATGACC-39
Antisense: 59-GTTTCATCCTGGAGCTTCTGCCTCA-39
GADPH Sense: 59-CATGACCACAGTCCATGCCATCACT-39
Antisense: 59-TGAGGTCCACCACCCTGTTGCTGTA-39
doi:10.1371/journal.pone.0005586.t001
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hole into the striatum (0.1 mm posterior, 4.0 mm ventral, and
2.0 mm lateral to the bregma). ICH was induced by the
administration of collagenase type IV (0.5 mL saline containing
0.078 U, Sigma) over a period of 5 min. After remaining in place
for another 3 min, the needle was gently removed.
Brain transplantation
F3 and F3.Akt1 hNSCs were dissociated into single cells by a
brief trypsin treatment and suspended in PBS at 4610
7 cells/
0.1 ml and kept on ice until transplanted. Randomly selected ICH
mice of one week after ICH surgery received 2 mL( 2 610
5 cells) of
F3.Akt1 cell suspension (n=9), F3 cell suspension (n=9) and killed
F3 cell suspension (n=10). F3 cells in glass tube were killed by
placing the tube in boiling water for 1 min, injected slowly for
5 minutes into overlying cortex of the hemorrhage lesion (0.1 mm
posterior, 2.0 mm ventral, and 2.0 mm lateral to the bregma). In
another control group, 2 mL of PBS was injected into the ICH
mice (n=10). Immunosuppressant was not used in any of the
animals. In order to identify the migration potential to the lesion
site of grafted cells, F3.Akt1 hNSCs were infected with an
adenovirus vector encoding LacZ gene (pAV.LacZ) in vitro at 100
MOI (PU/cell) for 24 hr before transplantation (n=2).
Behavioral Testing
Behavioral testing was performed weekly with the rotarod
(Harvard Instrument) by 2 individuals blinded to mice treatment
status [16,17]. In the rotarod test, mice were placed on the rotarod
cylinder, and the time the animals remained on the rotarod was
recorded. The speed was slowly increased from 10 to 40 rpm within
a period of 2 min. The trial was ended if the animal fell off the rungs
or gripped the device and spun around for 2 consecutive revolutions.
The animals were trained for 3 days before ICH operation. The
maximum duration (in seconds) on the device was recorded with 3
rotarod measurements 1 day before ICH induction. Motor test data
are presented as percentages of the maximal duration compared
with the internal baseline control (before ICH). The modified limb-
placing test is a version of a test previously described [16,17]. The
test consists of 2 limb-placing tasks that assess the sensorimotor
integration of the forelimb and the hind limb by checking responses
to tactile and proprioceptive stimulation. First, the mouse is
suspended 10 cm over a table, and the stretch of the forelimbs
toward the table is observed and evaluated: normal stretch, 0 points;
flexion with a delay (2 sec) and/or incomplete, 1 point; abnormal
flexion, 2 point. Next, the mouse is positioned along the edge of the
table, with its forelimbs suspended over the edge and allowed to
move freely. Each forelimb (forelimb, second task; hind limb, third
task) isgently pulled down, and retrieval and placement are checked.
Finally,the mouse isplaced towardthetable edge tocheckforlateral
placement of the forelimb. The 3 tasks are scored in the following
manner: normal performance, 0 points; performance with a delay
(2 sec) and/or incomplete, 1 point; no performance, 2 points. A
total of 9 points means maximal neurological deficit, and 0 points
means normal performance. Additionally, the body weights of all
animals were checked weekly for 8 weeks.
Histology and immunohistochemistry
Histology and immunohistochemistry of brain sections were
performed as described previously [16,17]. At the end of behavioral
testing, each animal was anesthetized and perfused through the
heart with cold saline followed by 4% paraformaldehyde in 0.1 M
phosphate buffer. The brains were post-fixed in same fixative for
24 hr, followed with followed with cryoprotection in 30% sucrose
for 24 hr and then 30 mm sections were prepared on a cryostat
(Leica CM 3000). The sections through the needle entry site which
was identifiable on the brain surface, and sites 1.0 mm anterior and
1.0 mm posterior to plane were processed for X-gal staining to
analyze the hemisphere area. These sections are representative of
the core of the ICH lesion. The morphometric analyses involved
computer-assisted hand delineation of the area of the striatum,
cerebral cortex, and ventricles, as well as the whole hemisphere.
Adjacent serial coronal sections were processed for double
immunofluorescence staining of human nuclear matrix antigen
(hNuMA, 1:100, mouse monoclonal, Oncogene) and antibodies
specific for cell type specific markers. Antibodies specific for
neurofilament low molecular weight protein (NF-L, 1:1000, rabbit,
Chemicon), neurofilament high molecular weight protein (NF-H,
1:1000, rabbit, Chemicon), microtubule associated protein-2
(MAP2, 1:500, rabbit, Chemicon), glial fibrillary acidic protein
(GFAP, 1:1000, rabbit, DAKO, Carpinteria, CA), and phospho-
Akt1 (1:100, rabbit, Upstate) were used for cell type identification of
neurons and astrocytes. Brain sections were incubated in mixed
solution of primary antibodies overnight at 4uC as free floating
sections, followed by mixed secondary antibodies of Alexa Fluor
488-conjugated anti-mouse IgG (1:1000, Molecular Probes, Eu-
gene, OR)and Alexa Fluor 594-conjugatedanti-rabbit IgG (1:1000,
Molecular Probes) for 1 hr at RT. Negative control sections from
each animal were prepared for immunohistochemical staining in an
identical manner except the primary antibodies were omitted.
Stained sections were then examined under an Olympus confocal
laser scanning biological microscope (Olympus, Tokyo, Japan).
Stereological cell counts
Total number of human NuMA-positive F3 (n=3) and F3.Akt1
(n=3) hNSCs in the brain sections from ICH animals was
determined by stereological estimation as described previously
[16,17]. The sections used for cell count covered the entire striatum
withhemorrhage lesion and overlyingcortex. This generally yielded
six or seven sections in a series. Sampling was done using the
Computer assisted stereological toolbox system, version 2.1.4
(Olympus), using an Olympus BX51 microscope, a motorized
microscope stage (Prior Scientific, Rockland, NY) run by an IBM
compatible computer, and a microcator (Heidenhain ND 281B,
Schaumberg, IL) connected to the stage and feeding the computer
withthe distance information in the z-axis. The counting areas were
delineated at a 1.256 objective and generated counting areas of
1506150 mm. A counting frame (1612 mm
2) was placed randomly
on the first counting area and systemically moved through all
counting areas until the entire delineated area was sampled. Actual
counting was performed using a 1006oil objective. Guard volumes
(4 mm from the top and 4–6 mm from the bottom of the section)
were excluded from both surfaces to avoid the problem of lost caps,
and only the profiles that came into focus within the counting
volume (with a depth of 10 mm) were counted. The estimate of the
total number of HuNuMA-positive F3 and F3.Akt1 calculated
according to the optical fractionator’s formula [35].
Statistical analysis
The statistical significance between group comparisons for
behavioral data was determined by one-way ANOVA and two-
way ANOVA. P values,0.001 were considered to be statistically
significant (version 12.0, SPSS, Chicago, IL).
Results
Stable human neural stem cell line overexpressing Akt1
F3 hNSC line was infected with a retroviral vector encoding
mouse Akt1 gene (Figure 1A), and clones resistant to hygromycin
Human Neural Stem Cells
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used in the present study. The morphology of the selected hNSC
line, F3.Akt1 does not differ from the parental F3 hNSCs with
bipolar- or multipolar-morphology (Figures 1B, C). Results of RT-
PCR analysis of mRNAs isolated from F3 and F3.Akt1 cells are
shown in Figure 1D. Transcripts for nestin (an NSC specific
marker), neurofilament triplet proteins (NF-L, NF-M and NF-H,
cell type-specific markers for neurons), glial fibrillary acidic protein
(GFAP, a specific marker for astrocytes) and Akt1 are all expressed
by both F3 and F3.Akt1 cells. However, GFAP band at F3.Akt1
lane detected was lighter than F3 parental cells. In addition
transcriptional level of Akt1 gene is higher in F3.Akt1 cells as
compared to parental F3 cells.
Hydrogen peroxide (H2O2)-Induced cell death
To determine the protective effects of Akt1 on the H2O2-
induced cell death in hNSCs, F3 and F3.Akt1 hNSCs were
exposed to varying concentration of H2O2. F3.Akt1 cells showed a
higher survival rate to H2O2 -induced cell death as compared to
the F3 controls (Figures 2A–C). Whether H2O2 induces changes in
phosphorylation status of Akt1 and caspase-3 cleavage in F3 and
F3.Akt1 cells was investigated. When F3 and F3.Akt1 cells were
exposed to 0.5 mM H2O2 for 6 hr, phosphorylated form of Akt1
and inactivated form of caspase-3 were found in F3.AKt1 cells
(Figure 2D), while F3 cells showed the opposite expression pattern
(Figure 2D). An increase in active fragment of caspase 3 (20 kDa)
was found in F3 cells following H2O2 treatment. These results
indicate that the enhanced cell survival of F3.Akt1 cells as
compared to parental F3 cells following H2O2 exposure is due
mainly from overexpression of Akt1 and its phosphorylation in
F3.Akt1 cell line. And there might be some mediators from Akt1 to
caspase-3 in signal pathway; we could consider that phospho-Akt1
finally inhibits caspase-3 cleavage and activation, thereby provides
neuroprotection of the hNSCs.
Functional recovery in ICH animals by hNSC
transplantation
Motor performance of ICH animals receiving PBS, F3 Killed,
F3 or F3 Akt1 hNSCs was determined by the rotarod and
neurology score (Figures 3A, B). The ICH mice receiving F3.Akt1
hNSCs showed improved behavioral performance on the rotarod
compared with the PBS, F3.killed control groups, and the effect
persisted for at least up to 8 weeks post-transplantation (PT, the
point at which animals were sacrificed) (Figure 3A). Significant
difference in rotarod test performance in F3.Akt1 vs F3 groups
detected during the period of only 5 weeks PT (P,0.05). The
F3.Akt1 transplantation group also showed marked improvement
in the limb placement beginning 2 weeks PT and persisting for at
least up to 8 weeks (Figure 3B). No significant difference in
behavioral performance in F3.Akt1 vs F3 groups detected during
the period of 1,8weeks PT.
Figure 1. Characterization of human NSC lines. A: The retroviral vector encoding Akt1 (pLHCX.Akt1) used in the present study for the
generation of HB1.F3.Akt1 (F3.Akt1) human neural stem cell (NSC) line. B and C: Phase contrast microscopy of F3 and F3.Akt1 human NSCs. Bar
inciates 20 mm. D: Gene expression of cell type-specific markers as studied by RT-PCR in F3 and F3.Akt1 human NSCs. Both of F3 and F3.Akt1 NSC
lines express cell type-specific markers Nestin (for neural stem cells), NF-L, NF-M and NF-H (for neurons), GFAP (for astrocytes) and Akt1.
doi:10.1371/journal.pone.0005586.g001
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astrocytes
At 7 days after induction of experimental ICH, 2610
5 cells/2 ml
of F3 or F3.Akt1 hNSCs were transplanted into ICH mouse
cerebral cortex overlying hemorrhage lesion site, 2 mm cranial to
the hemorrhagic lesion. LacZ+ human NSCs migrated selectively
to the hemorrhagic core and also located on the border of the
hemorrhagic core and further away from the injection sites
(Figures 4A–C). A large number of transplanted hNuMA (human
specific nuclear matrix antigen)-positive F3.Akt1 cells (35–45%)
differentiated into NF-H+ neurons in the peri-hematomal sites
Figure 2. Cell viability increases to H2O2–induced oxydative
stress conditions and Akt1 phosphorylation in F3.Akt1 human
NSCs. A: Phase contrast microscopy of F3 and F3.Akt1 human NSCs
following exposure to 0.5 mM H2O2 for 6 hr. F3.Akt1 NSCs survived well
as compared to the parental F3 NSCs. B and C: F3.Akt1 NSCs were found
to show resistance to H2O2-induced cell death as compared to control
Figure 3. Behavioral improvement demonstrated in intracere-
bral hemorrhage (ICH) mice transplanted with F3 or F3.Akt1
human NSCs. A: Rotarod test. F3.Akt1-transplanted group showed
better performance than PBS controls or F3 cell group, killed F3.Akt1
cell group 8 days onward, and these benefits continued up to 8 weeks
post-transplantation (* P,0.05). B: In the modified limb placement test,
F3.Akt1-transplanted group showed better performance than PBS, F3 or
killed F3.Akt1 group (* P,0.05).
doi:10.1371/journal.pone.0005586.g003
parental F3 NSCs at 6 hr (B) and 24 hr (C) respectively. D: Western blot
analyses of protein levels of phopho-Akt1 and caspase-3 enzymes in F3
and F3.Akt1 NSCs following H2O2 treatment. F3.Akt1 NSCs showed an
increased level of Akt1 phosphorylation, while the level in activation
form of caspase-3 was reduced under the H2O2 treatment (* p,0.05, **
p,0.001).
doi:10.1371/journal.pone.0005586.g002
Human Neural Stem Cells
PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5586(Figures 4D–F). While only a small number of transplanted
hNuMA+ F3.Akt1 cells (,4%) were GFAP+ astrocytes and the
hNuMA+/GFAP+ double-positive cells were found along the
border of hemorrhagic core (Figures 4G–I). These results indicate
that a large portion of grafted F3.Akt1 cells differentiate into either
neurons or astrocytes in response to signals from the local
microenvironment provided by the hemorrhagic lesion.
Survival of transplanted F3 and F3.Akt1 hNSCs in ICH
brain
Identification of grafted F3.Akt1 hNSCs in ICH brain was
determined by immunostaining with hNuMA (Figure 5). Total
numbers of hNuMA-positive F3 and F3.Akt1 hNSCs in the ICH
brain sections were carried out using stereological estimation at 2-
and 8-weeks post-transplantation (PT). Cell survival rate of
Figure 4. LacZ (beta-galactosidase)-labeled F3.Akt1 human NSCs in intracerebral hemorrhage (ICH) mouse brain at 2 weeks post-
transplantation. A: One week after an ICH lesion (an intrastriatal injection of collagenase), LacZ -labeled F3.Akt1 NSCs were transplanted into the
cortex overlying the ICH lesion. Two weeks post-transplantation, LacZ-positive F3.Akt1 NSCs were found to migrate extensively into the hemorrhage
core and surrounding brain sites. Bar indicates 50 mm. B–D: Higher magnification of indicated areas. Bar indicates 20 mm. E–G: Double
immunofluorescent staining of engrafted F3.Akt1 human NSCs in ICH mouse brain 8 weeks post-transplantation. F3.Akt1 NSCs in the lesion sites are
found to differentiate into neurons as shown by double staining of human nuclear matrix antigen (hNuMA) and neurofilament protein (NF-H, a
neuron specific marker). H–J: F3.Akt1 human NSCs in the lesion sites are found to differentiate into astrocytes (arrows) as shown by double staining of
human nuclear matrix antigen (hNuMA) and glial fibrillary acidic protein (GFAP, an astrocyte specific marker). Bar indicates 20 mm.
doi:10.1371/journal.pone.0005586.g004
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initial population of 200,000 cells) and at 8 weeks PT the number
is 64,89061940 cells (33% of the initial population), while in
control parental F3 hNSCs cell survival at 2 weeks PT is
78,32061250 cells (39% of the initial population of 200,000 cells)
and 32,54064920 cells (16% of the initial population of 200,000
cells) at 8-weeks (p,0.05) (Figure 5). These results indicate that
Akt1 overexpression in hNSCs resulted in a 40% increase in cell
survival of transplanted hNSCs at 2 weeks PT and 100% increase
at 8 weeks PT. In addition, F3.Akt1 human NSCs grafted in
cortex overlying striatum were found to migrate extensively to
hippocampus 8 weeks PT (Figure 6) indicating that F3.Akt1
hNSCs are capable of migrating to distant anatomical site.
To determine whether Akt1 expression in F3.Akt1 cells induces
their own proliferation, expression of cell proliferation marker Ki-
67 was examined in ICH brain sections (Figure S1). Transplanted
F3.Akt1 cells identified as hNuMA-positive cells were immunore-
action-negative for proliferation marker Ki-67 indicating that the
grafted F3.Akt1 cells did not continue to proliferate following
transplantation. Furthermore there was no sign of tissue distortion
or tumor formation in brain of ICH animals grafted with F3 or
F3.Akt1 hNSCs 6 months PT (Figure S2). Good survival of hNSCs
was found in the hNSC injection path into striatum two days after
transplantation (Figure S3).
Discussion
In the present study, mouse ICH model was used to provide
proof-of-principle that hNSCs genetically modified to express
Akt1, a general mediator of cell survival signals, can be
transplanted in the brain of animal models of neurological
diseases, and produces beneficial effects of increased survival of
grafted NSCs and consequent functional recovery. We demon-
strate that brain transplantation of hNSCs overexpressing Akt1 in
Figure 5. At 2 weeks post-transplantation (PT) in the hemorrhage core border areas, difference in number of human nuclear matrix antigen
(hNuMA)-positive cells between ICH-F3 control group (A) and ICH-F3.Akt1 group (C) is not apparent, but at 8 weeks PT number of hNuMA-positive
cells is much higher in F3.Akt1-ICH group (D) as compared to control F3-ICH group (B). Bar indicates 100 mm. E: Percentage of hNuMA-positive cells
found in hemorrhage core border area is higher in ICH-F3.Akt1 group as compared to ICH-F3 group at both 2 and 8 weeks post-transplantation.
doi:10.1371/journal.pone.0005586.g005
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motor performance as determined by rotarod and limb placement
tests, increased survival of grafted NSCs, and differentiation of
grafted NSCs into neurons and astrocytes. These results are
consistent with previous studies that Akt1, protein which is known
as a general mediator of cell survival signals, promotes the survival
of CNS neurons in vitro [23,27–29], and provides favorable clinical
outcome in animal models of ischemia [36].
In the present study we exposed F3 and F3.Akt1 hNSCs to
hydrogen peroxide injury in vitro to study the neuroprotectiion
provided by Akt1 under the conditions of oxidative stress, and the
results indicate that F3.Akt1 cells showed a higher survival rate
following H2O2 -induced injury as compared to the F3 controls
(Figs. 2A–C). Following H2O2 treatment, phosphorylation of Akt1
and concomitant inactivation of caspase-3 were found in F3.AKt1
cells, while in control F3 cells non-phosphorylation of Akt1 and an
increase in active fragment of caspase 3 were found (Fig. 2D). It is
known that Akt1 phosphorylates caspase-9 at Ser-196, thereby
blocking cytochrome c-mediated caspas-9 activation and inacti-
vation of caspase-3 leading to inhibition of proapoptotic signals
[37]. Recent studies have also shown that antioxidant enzymes
such as glutathione peroxidase-1 (Gpx1), Cu/Zn-superoxide
dismutase (Cu/Zn-SOD) and heme oxygenase-1 (HO-1) are
target substrates of activated Akt and results in modulation of
redox system and reduced toxic levels of reactive oxygen species
(ROS) in various cell types [38–40].
From as early as 8-day post-transplantation (PT) to 8-weeks PT,
F3.Akt1 hNSCs induced an increased survival of transplanted
NSCs in the host brain. Survival of transplanted F3.Akt1 hNSCs
in ICH mouse brain was identified by human nuclear matrix
antigen (hNuMA)- or LacZ/b-gal-positive reaction. The cell count
in ICH brain indicates that 40% increase in cell survival in
F3.Akt1 group over control F3 group and 100% increase at 8-
weeks PT. It should be noted that the majority of grafted F3.Akt1
cells differentiated into either neurons (b-tubulin III-, NF-L- or
NF-H-positive) or astrocytes (GFAP-positive) along the border of
lesion sites (Fig. 4). In addition, a majority of grafted F3.Akt1
hNSCs differentiated into either neurons or astrocytes in response
to signals provided in the local microenvironment.
Previous studies have reported that the activation of PI3K/Akt
signaling axis promotes growth and survival of tumor cells, and
genetic perturbation of this pathway increases the survival of
cancer cells [41–43]. For that reason, we were very concerned
about possible tumorigenesis in the animals transplanted with
F3.Akt1 hNSCs. Transplanted F3 or F3.Akt1 hNSCs in ICH
lesion sites were immunoreaction-negative for cell proliferation
marker Ki-67 (supplementary Fig. 1) indicating that hNSCs do not
proliferate actively in vivo environment. In addition, none of the
animals grafted with F3.Akt1 or F3 hNSCs showed tumor
formation upon histological examination even in animals with 6-
months PT (Supplementery Fig. 2).
Akt activity is induced following PI3K activation in various
growth factor-mediated signaling cascades [23]. The PI3K-Akt
signal pathway is well-known for the cell survival and it exhibits
anti-apoptotic effects against a variety of apoptotic paradigms
including withdrawal of extracellular signaling factors, oxidative
and osmotic stress, irradiation and ischemic shock [24–27]. Akt
regulates cell growth and survival mechanisms via phosphorylation
of a large number of substrates such as Forkhead transcription
factors (FOXO), GSK-3, BAD, caspase-9 and MDM2, and many
of these proteins contribute to antiapoptotic signaling in various
cell types [24–27]. Activation of PI3K/Akt signaling pathway
promotes extended survival of neuronal cell types from cell death
caused by injuries, including cerebellar granule cells [23] and
hippocampal neurons [27–29].
Akt1 as well as its downstream molecules offer great promise for
the development of therapeutics against a number of neurological
disorders such as stroke, spinal cord injury and neurodegenerative
diseases such as Alzheimer disease, Parkinson disease and ALS.
Initially believed to have cellular functions directed primarily toward
cell survival and growth, Akt1 is now seen as a potential broad
cytoprotective agent. Akt1 can offer cellular protection not only
through the modulation of intrinsic apoptotic machinery, but also
throughtheactivationofsurvivalsignalpathways.Akt1drivescellular
survival signals through a series of distinct pathways that involve the
Forkhead family of transcription factors, GSK-3b, b-catenin, eIF2B,
c - J u n ,C R E B ,B a d ,I K K ,p 5 3 ,a n dJ I P s[ 2 5 , 2 6 ] .Y e t ,i ti se v i d e n tt h a t
further work that clarifies the cellular environment controlled by Akt1
will be of exceptional value to refine our knowledge of Akt1 and to
maximize the potential of this protein as a therapeutic agent.
Supporting Information
Figure S1 Whether Akt1 expression in F3 or F3.Akt1 NSCs
causes proliferation in vivo, cell proliferation marker Ki-67 was
Figure 6. Survival of grafted F3.Akt1 human NSCs in hippo-
campus was demonstrated by immunoperoxidase microscopy
of hNuMA at 8 weeks post-transplantation (PT). A: Lower
magnification of hippocampus 8 weeks PT. Bar indicates 1 mm. B:
F3.Akt1 human NSCs grafted in cortex overlying striatum were found to
migrate extensively to hippocampus 8 weeks PT. Bar indicates 50 mm.
doi:10.1371/journal.pone.0005586.g006
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PLoS ONE | www.plosone.org 8 May 2009 | Volume 4 | Issue 5 | e5586examined immunochemically in brain sections. Transplanted F3
or F3.Akt1 cells (hNuMA-positive/green) are immunoreaction-
negative for cell proliferation marker Ki-67 (red). Ki-67-positive
cells represent host mouse brain cells. A: Control parental F3
NSCs. B: F3/Akt1 NSCs.
Found at: doi:10.1371/journal.pone.0005586.s001 (0.30 MB TIF)
Figure S2 A: Hematoxylin and Eosin-stained section of mouse
brain transplanted with F3.Akt1 NSCs. Six months post-
transplantation. Transplantation of v-myc-immortalized F3 or
F3.Akt1 human NSCs did not cause tumor formation in the brain.
B: Inset indicates higher magnification of the marked area.
Found at: doi:10.1371/journal.pone.0005586.s002 (1.21 MB TIF)
Figure S3 A: A schematic drawing of the ICH brain in which b-
gal-labeled human NSCs were transplanted. Two days post-
transplantation. The circle in the neostriatum represents hemor-
rhagic core, and the marked areas B and C represent NSC
injection path. B–C: Higher magnification of the marked areas
where large number of b-gal-labeled NSCs is found.
Found at: doi:10.1371/journal.pone.0005586.s003 (0.42 MB TIF)
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